Early Life
Jose Luis Rubiralta inherited his stake in Werfen in 2012, building on the legacy of his father, Josep Maria Rubiralta, who co-founded Izasa, the predecessor to Werfen, in 1966. The family's roots are deeply intertwined with the healthcare sector, establishing a foundation for Jose Luis's future career and wealth.
Rise to Success
Werfen has grown into one of Spain's largest diagnostic companies, operating in over 30 countries and employing approximately 7,000 people. Jose Luis Rubiralta has been a key figure in the company's governance, serving on the board since 2013. His involvement has coincided with Werfen's strategic acquisitions and expansion, solidifying its position in the global diagnostics market.
Key Business Strategies
Werfen's success is built on several key strategies. The company focuses on research, development, manufacturing, and distribution of diagnostic systems used in hospitals and clinical laboratories. Werfen is also known for its investment in R&D, spending approximately 8-9% of sales in this area in 2024, which has contributed to its innovation in the in-vitro diagnostics (IVD) field. Werfen has made key acquisitions, including Immucor, a US-based company, which has expanded its portfolio and strengthened its presence in the market. The company has also made acquisitions such as TEM (Germany) and Accriva Diagnostics (USA), further expanding the company.
Philanthropy
While specific philanthropy amounts are not readily available, the Rubiralta family is involved in philanthropic initiatives. The family is associated with Fundacion Privada Nous Cims, focused on health and education projects, particularly in Senegal.
